Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoST substudy of tildrakizumab in advanced osteosarcoma or soft tissue sarcoma
ACTRN12620000984998Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tildrakizumab in osteosarcoma (OS) and soft tissue sarcoma (STS), sponsored by The University of Sydney. Primary endpoint: Clinical activity by objective tumor response or time-to-progression ratio. Started Mar 2021; status: completed.
02
Drugs
tildrakizumab
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ACTRN12620000984998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000984998.